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Abstract
We sought to identify a secreted biomarker for b-catenin activation commonly seen in hepatocellular carcinoma (HCC). By
examination of our previously published genearray of hepatocyte-specific b-catenin knockout (KO) livers, we identified
secreted factors whose expression may be b-catenin-dependent. We verified expression and secretion of the leading factor
in HCC cells transfected with mutated (Hep3BS33Y)-b-catenin. Serum levels of biomarker were next investigated in a mouse
model of HCC with b-catenin gene (Ctnnb1) mutations and eventually in HCC patients. Leukocyte cell-derived chemotaxin-2
(LECT2) expression was decreased in KO livers. Hep3BS33Y expressed and secreted more LECT2 in media as compared to
Hep3BWT. Mice developing HCC with Ctnnb1 mutations showed significantly higher serum LECT2 levels. However patients
with CTNNB1 mutations showed LECT2 levels of 54.28622.32 ng/mL (Mean 6 SD; n = 8) that were insignificantly different
from patients with non-neoplastic chronic liver disease (32.8621.1 ng/mL; n = 15) or healthy volunteers (33.267.2 ng/mL;
n = 11). Intriguingly, patients without b-catenin mutations showed significantly higher serum LECT2 levels (54.26 6
22.25 ng/mL; n = 46). While b-catenin activation was evident in a subset of non-mutant b-catenin HCC group with high
LECT2 expression, serum LECT2 was unequivocally similar between b-catenin-active and -normal group. Further analysis
showed that LECT2 levels greater than 50 ng/ml diagnosed HCC in patients irrespective of b-catenin mutations with
specificity of 96.1% and positive predictive value of 97.0%. Thus, LECT2 is regulated by b-catenin in HCC in both mice and
men, but serum LECT2 reflects b-catenin activity only in mice. Serum LECT2 could be a potential biomarker of HCC in
patients.
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Introduction
Primary liver cancer, which is predominantly hepatocellular
carcinoma (HCC), is the sixth most common cancer worldwide
and the third most frequent cause of cancer mortality [1]. b-
Catenin gene (CTNNB1) mutations are one of the major oncogenic
gene alterations in HCC seen in 10–40%, while mutations
affecting Axin1 are seen in around 10% of all HCCs [2]. CTNNB1
mutations are observed in exon-3 that contain phosphorylation
sites essential for b-catenin degradation leading to its stabilization
and enhanced expression of target genes such as glutamine synthetase
(GS), axin2 and regucalcin [3,4,5,6]. This mutation is mutually
exclusive to p53 mutation, which is the most common mutation in
HCC [7,8]. No routine test is currently available that can yield any
genetic information relevant to HCC. Since biopsies for HCC
carry high risk because HCCs are usually associated with an
underlying liver disease, serum biomarkers specific for a molecular
aberration may be highly relevant in personalized medicine in
Oncology.
LECT2 is a 16 kDa chemotactic protein purified from human
T-cell line [9]. Since hepatocytes are the chief source, expression
of LECT2 is specific for liver [10]. LECT2 is a direct target of b-
Catenin and has been shown to have a role in the pathogenesis of
HCC [11]. In a mouse liver tumor model, LECT2 prohibits tumor
progression by regulating Th2-based inflammation [12]. Although
its role is well known as chemokine-like secreted protein involved
in inflammation, there is no investigation about its serum levels
especially in the setting of liver tumor development.
Here, screening a previously published Affymetrix gene array,
we identify Lect2 expression to be decreased in hepatocyte-specific
b-catenin knockout livers [13]. Next, using an in vitro analysis in
human HCC cells, we demonstrate that indeed LECT2 expression
and its protein levels reflect b-catenin activity and hence
hypothesize that it may be a good biomarker for HCC with b-
catenin activation. The utility of LECT2 as a biomarker was
validated first in a mouse liver tumor model where exon-3
mutation in b-catenin gene and ensuing b-catenin activation is
implicated in HCC pathogenesis [14,15]. However, in HCC
patients, serum LECT2 levels were not significantly different in
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tumor with CTNNB1 or without CTNNB1 mutations when
compared to patients with chronic liver disease or healthy
volunteers. Furthermore, despite b-catenin activation observed in
an additional subset of non-CTNNB1 mutated HCC, which
showed high LECT2 expression, serum LECT2 levels were not
predictive for active b-catenin signaling in the tumor. Interestingly
though, irrespective of molecular aberrations, LECT2 levels were
significantly higher in all HCC patients versus patients with
cirrhosis or healthy controls. In fact, serum LECT2 $ 50 ng/ml
indicated HCC with high specificity and positive predictive value.
Materials and Methods
Cell lines and treatment
Human HCC cell lines, Hep3B, HepG2, SNU449, SNU398,
and HuH7, were obtained from the American Type Culture
Collection (Manassas, VA). Cells were cultured in Eagle’s minimal
essential medium (EMEM) or RPMI supplemented with 10% vol/
vol FBS at 37uC in a humidified 5% carbon dioxide atmosphere.
For siRNA knockdown experiment, the cells were transfected
using Lipofectamine 2000 (Life Technologies, Grand Island, NY)
with b-catenin (CTNNB1) or scrambled Negative Control siRNAs
(Ambion, Grand Island, NY) as previously described [16]. Wild
type b-Catenin gene (WT) or b-Catenin gene mutated at serine 33
to tyrosine (S33Y), which is constitutively active, were stably
transfected into Hep3B cells to generate Hep3BWT and
Hep3BS33Y, respectively, as described previously [17].
Animal studies
All animal experiments were performed under the guidelines of
the National Institutes of Health and the Institutional Animal Use
and Care Committee at the University of Pittsburgh and approved
by the Institutional Animal Use and Care Committee at the
University of Pittsburgh. C3H/He mice were injected intraperi-
toneally with DEN (Sigma-Aldrich, Inc.) at a dose of 90 mg/gram
body weight at 6 weeks of age and 3 weeks later putting them on a
diet containing 0.05% phenobarbital (PB) until sacrifice at 6–8
months. Serum was collected at time of euthanasia and
simultaneously, liver tissues were collected for histology and
protein analysis.
Mutation analysis
Genomic DNA was extracted using DNA Micro Kit (Qiagen,
Valencia, CA) from both the frozen liver sections after hematoxilin
and eosin (HE) staining (Sigma-Aldrich, Inc.) to identify the tumor
and from patient’s frozen liver tumor tissues. Amplification of exon
3 of b-catenin gene (CTNNB1) using polymerase chain reaction
(PCR), gel extraction, purification of PCR products, and direct
sequencing were performed as described previously [18].
Immunohistochemistry and Western blot
Immunohistochemical staining and Western blot was performed
as described previously [19]. Rabbit polyclonal anti-GS (Santa
Cruz, 1:100 dilution) was used in immunohistochemistry. Anti-
bodies used in Western blot were mouse monoclonal anti-b-
Catenin antibody (Santa Cruz, 1:1000 dilution), goat polyclonal
anti-LECT2 antibody (Santa Cruz, 1:100 dilution), and rabit
polyclonal anti-GAPDH (Santa Cruz, 1:1000 dilution).
Real-time polymerase chain reaction
In mice analyses, total RNA was extracted from frozen sections
after H&E staining using a mirVana microRNA isolation kit
(Ambion) in accordance with the manufacturer’s instructions.
After reverse transcription and DNase treatment were performed,
qRT-PCR was performed on a StepOne Plus using 26 SYBR
Green PCR Master Mix (Applied Biosystems, Foster, CA). The
primers’ sequences are as follows: Glutamine Synthetase (encoded by
Glul) forward, 59- CTCGCTCTCCTGACCTGTTC -39 and
reverse, 59- TTCAAGTGGGAACTTGCTGA -39; LECT2 for-
ward, 59- CCCACAACAATCCTCATTTCA -39 and reverse, 59-
GTTAGCCCATGGTCCTGCTA -39; GAPDH was used as an
internal control.
In human analyses, total RNA was extracted from frozen tissues
and qRT-PCR analysis performed as described previously [20].
Enzyme-linked immunosorbent assay (ELISA)
Serum LECT2 levels were measured by either human or mouse
LECT2 ELISA kit (Medical & Biological Laboratories (MBL) Co,
Ltd, Niigata, Japan) according to the manufacture’s protocol.
Clinical tissue and serum samples
All tissues and materials used in this study were obtained under
an approved Institutional Review Board protocol at the University
of Pittsburgh and Kumamoto University. Specifically, frozen
tissues and serum samples were obtained from HCC patients in
the Department of Surgery, University of Pittsburgh (Pittsburgh,
PA; n = 20) with a written informed consent approved by the
University of Pittsburgh Institutional Review Board. Frozen tissues
and serum samples from HCC patients were also collected by the
Department of Gastroenterological Surgery, Kumamoto Univer-
sity (Kumamoto, Japan; n= 45), with a written informed consent
approved by the Institutional Review Board at the Kumamoto
University. Additional serum samples were obtained from patients
with chronic liver disease (n = 15) in the Department of Medicine
that did not have any evidence of HCC as determined by normal
serum a-fetoprotein and negative abdominal ultrasound or CT
scan within 6 months of serum collection. These patients also
signed informed consent prior to providing serum samples and the
University of Pittsburgh Institutional review board approved the
study.
Chromatin immunoprecipitation (ChIP)
ChIP Assay was performed using Hep3BWT and Hep3BS33Y
cells (Cambridge, MA). 36106 cells were fixed with 1%
formaldehyde for 10 min, incubated with glycine (0.125 M) for
5 min, and then washed twice with PBS. After a short spin, the
pellets were resuspended in cell lysis buffer (5 mM PIPES, pH8.0,
85 mM KCl, 0.5% NP-40) by pipetting. After centrifugation, the
pellets were resuspended in nuclear lysis buffer (50 mM Tris,
pH8.1, 10 mM EDTA, 1% SDS) containing protease inhibitors by
pipetting, and sonicated to break chromatin into fragments of
around 0.3–1.0 kb length. Subsequent IP experiment was
performed with ChIP-IT High sensitivity kit (Active motif,
Carlsbad, CA). The diluted DNA-protein complex (25 mg of
protein) was incubated overnight at 4uC with different antibodies
(rabbit anti-TCF4, Cell Signaling Technology; rabbit IgG and
goat anti-HNF1a, Santa Cruz) in the presence of herring sperm
DNA and protein A/G agarose beads. PCR was performed using
primers for LECT2 promoter region: 59- CAGCCCAGAA-
GACTGTCGAT -39 (forward) and 59- GATTAGAGTTGC-
CCCCACAC -39 (reverse); albumin promoter region, 59-
TGGAGAAAACAGTTCCAGATGGT -39 (forward) and 59-
CGTGTGGGGTTGACAGAAGA -39 (reverse).
Cell culture and luciferase Assay
SNU449 cells were plated in 24 well plate and treated with
either 50 nM control si-RNA or 50 nM b-Catenin si-RNA with
Lect2 as HCC Biomarker
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lipofectamine iMAX (Invitrogen). TOPFLASH reporter plasmid
was transfected using the lipofectamine 2000 (Invitrogen) a day
after the siRNA treatment. Subsequently, cells were treated with
TGF-b1 (5 ng/mL) (R&D system) for 24 hours. Cells were lysed
and prepared using the luciferase reporter assay system (Promega,
Madison, WI). Reporter activity was read on a luminometer
(Lumat; EG & G Berthold).
Statistical analysis
Statistical analysis was performed using the JMP 8.0 software
(SAS Institute, Cary, NC, USA). Values were presented as the
mean 6 standard deviation (SD). Differences between two
variables were calculated using the Wilcoxon test. Multiple
samples were compared by ANOVA followed by Tukey-Kramer
post hoc test. P,0.05 was considered to indicate a statistically
significant difference.
Results
Identification of LECT2 regulation by b-Catenin
To identify specific biomarkers for b-catenin upregulation, we
utilized our previous dataset of microarray analysis comparing
gene expression of liver tissue of hepatocyte-specific b-catenin
knockout (KO) with that of wild type (WT) [13]. From a list of
2963 upregulated genes in WT as compared to KO (with fold
Figure 1. Regulation of LECT2 expression by b-catenin. A. Strategy to identify biomarker for b-catenin activation. Microarray analysis was
performed using liver tissue from hepatocyte-specific b-catenin knockout (KO) and wild-type (WT) mice, which identified 14 secreted targets. Lect2
expression was 117-fold lower in KO livers. B. b-Catenin expression in Hep3B cells and stable cell lines established with wild-type b-catenin (Hep3B
WT)- or mutated b-catenin (Hep3B S33Y)-transfected cells. C. Representative Western blot shows increased LECT2 protein levels in Hep3B S33Y cells
as compared to Hep3B WT. D. Hep3B S33Y cells transfected with either b-catenin or control siRNA showed decreased b-catenin and LECT2 protein
levels in a representative Western blot. E. Increased LECT2 protein levels were observed in culture media collected from Hep3B S33Y cells as
compared to Hep3B WT as analyzed by ELISA. Basal media was used as a negative control. F. Occupation of Lect2 promoter by TCF4 especially in
Hep3B S33Y cells was as assessed by ChIP. Albumin promoter is not regulated by b-catenin but by HNF1a, which is used as quality control for
chromatin.
doi:10.1371/journal.pone.0098817.g001
Table 1. Candidate genes encoding secreted protein.
Gene Name
Lect2 leukocyte cell-derived chemotaxin 2
AFP alpha fetoprotein
Slpi secretory leukocyte protease inhibitor
Del1 del1 minor splice variant
Clecsf8 C-type lectin, superfamily member 8
Sh2d1a SH2 domain protein 1A
Wnt10a wingless related MMTV integration site 10a
IL22b interleukin-22b
Egf epidermal growth factor
Fgf13 fibroblast growth factor-related protein FGF-13
Wnt4 wingless-related MMTV integration site 4
Igf2 insulin-like growth factor 2
Fdp fibrocyte-derived derived protein
Scya24 eotaxin-2
doi:10.1371/journal.pone.0098817.t001
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change . 5), we identified 14 genes that encode for secreted
proteins (Table 1). The leading candidate lect2 showed a 117-fold
lower expression in KO as compared to WT (Figure 1A). To
validate if LECT2 expression could be induced by b-catenin
activation, we used two previously generated stable human cell
lines, Hep3B cells expressing wild type b-catenin (Hep3BWT) and
Hep3B cells expressing S33Y-mutated b-catenin (Hep3BS33Y), the
latter showing highest b-catenin levels (Figure 1B) [17]. We
compared LECT2 expression between these cell lines using qRT-
PCR analysis and detected a notable increase in its expression in
Hep3BS33Y cells (data not shown). Whole cell lysates also showed
increased LECT2 protein levels in Hep3BS33Y as compared to
Hep3BWT cells (Figure 1C). To see if LECT2 upregulation is
caused by active b-catenin, Hep3BS33Y were transiently transfect-
ed with b-catenin or control siRNA. b-Catenin knockdown led to
a notable decrease in LECT2 protein levels (Figure 1D).
Next, to assess if LECT2 is being secreted, conditioned media
was collected from Hep3BWT and Hep3BS33Y cells and subjected
to ELISA assay. Significantly higher LECT2 protein was detected
in conditioned media from Hep3BS33Y (0.2960.13 ng/mL) as
compared to Hep3BWT cells (0.02360.046 ng/mL) (Figure 1E).
Basal media, used a negative control, also showed lack of any
LECT2 protein (0.01760.057 ng/mL).
Figure 2. Serum LECT2 levels in mice with b-catenin gene mutated HCC. A. Representative picture of b-catenin (left panel) and GS (right
panel) immunohistochemistry of liver of a tumor bearing mouse at 8 months after DEN/PB treatment. Magnification, 1006. B. Using frozen tissue
from a representative tumor, b-catenin gene exon-3 mutation affecting codon 33 (red box) was confirmed by direct sequencing. C. Serum LECT2
levels were significantly (*) increased in tumor bearing versus non-tumor bearing DEN/PB treated mice as analyzed by ELISA. (* p,0.01). D.
Representative pictures of frozen sections from which tumors (T1-T3) were scraped for direct sequencing. E. Sequence analysis from three tumor
lesions (T1-T3) show S33Y-b-catenin gene mutations in codon 33 (red boxes) by direct sequencing. F. Glutamine Synthetase (Glul) and Lect2 expression
in three tumor lesions (T1-T3) were assessed by qRT-PCR. Gene expression of background liver tissues surrounding tumor are shown as N.
doi:10.1371/journal.pone.0098817.g002
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Figure 3. No correlation of b-catenin mutations or b-catenin activation to serum LECT2 levels in patients. A. Serum LECT2 levels in
patients with HCC with CTNNB1 mutations, absent CTNNB1 mutations, patients with chronic liver fibrosis (CH/LC), and healthy volunteer (HV) as
assessed by ELISA. (*p,0.05). B. No correlation observed between LECT2 expression in tumor and serum levels of LECT2 in HCC patients (n = 28). C. No
correlation observed between LECT2 expression in b-catenin mutated tumors and serum levels of LECT2 in these HCC patients (n = 4). D. No
Lect2 as HCC Biomarker
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Lastly, to specifically determine if b-catenin-T cell factor (TCF)
signaling was indeed regulating LECT2 expression, chromatin
immunoprecipitation (ChIP) analysis was performed on extracts
from Hep3BS33Y and Hep3BWT cells. As shown in figure 1F,
LECT2 was pulled down with TCF4 and not control IgG in
Hep3BS33Y cells. This indicates promoter activity driven by TCF4-
b-catenin in Hep3BS33Y cells. Albumin, whose expression is b-
catenin-TCF independent, was pulled down by HNF1a in both
Hep3BS33Y and Hep3BWT cells. These results show occupancy of
Lect2 promoter by TCF4, thus demonstrating its regulation by the
b-catenin-TCF signaling.
HCC with b-Catenin mutation increases serum LECT2
level in mice
To investigate if Lect2 could be a serum biomarker in mice, we
used a murine HCC model, which utilizes b-catenin signaling as a
major mechanism of carcinogenesis. Tumor induction by a single
injection of diethylnitrosamine followed by exposure to PB as
described in methods and elsewhere has been shown to select for
exon-3 mutations in b-catenin gene to give rise to HCC at 6-8
months [14,15]. Indeed, HCC observed in mice with this protocol
were strongly GS-positive and had nuclear b-catenin accumula-
tion as observed by immunohistochemical staining (Figure 2A).
Genetic alteration in b-catenin gene contributing to b-catenin
activation was confirmed by direct sequencing (Figure 2B). We
could recognize liver tumor formation in 9 mice out of 13 that
were subjected to DEN/PB protocol. Strikingly, the 9 mice with
evidence of histological tumor burden showed significantly (p,
0.01) higher serum Lect2 levels (55.9619.9 ng/mL) as compared
to the 4 non-tumor bearing mice (24.965.5 ng/mL) (Figure 2C).
To confirm mutations in b-catenin gene due to existing tumor
heterogeneity and also verify corresponding Lect2 expression, we
extracted both genomic DNA and total RNA from same nodules
(Figure 2D). Direct sequencing showed a common mutation
(S33Y) in T1, T2 and T3 nodules (Figure 2E). We next examined
Lect2 mRNA expression as well as Glul mRNA (encoding GS
protein) expression in these tumor nodules. All 3-tumor nodules
had high Lect2 and Glul expressions as compared to the
background liver (Figure 2F). Thus, in mice Lect2 expression and
eventually its secretion is upregulated by b-catenin mutations in
HCC, which can be detected in serum and hence may be a useful
biomarker in this mouse model.
Serum LECT2 level is inconsistent with b-Catenin
mutations in human HCC
Sera were available from 54 HCC patients through appropriate
IRB approvals. Eight of the 54 patients showed b-catenin gene
(CTNNB1) alterations in the form of missense mutations in exon-3
(Table 2). Remaining 46 patients lacked any genetic alterations in
exon-3 of CTNNB1. Additionally, we enrolled healthy volunteers
and also patients with cirrhosis due to chronic liver disease
(Table 3) to determine serum LECT2 levels and address its
efficacy as a tumor marker. Based on Tukey-Kramer post hoc test,
serum LECT2 levels in patients with mutated b-Catenin
(54.28622.32 ng/mL; n= 8) were not statistically different from
either patients with cirrhosis (32.8621.1 ng/mL, p=0.091;
n = 15) or healthy volunteers (33.267.2 ng/mL, p=0.137;
n = 11). On the other hand, patients who did not harbor CTNNB1
mutations showed significantly higher LECT2 level
(54.26622.25 ng/mL; n= 46) than those with cirrhosis and from
healthy volunteers (p=0.0044 and 0.0176, respectively)
(Figure 3A).
To address if serum LECT2 levels showed any correlation with
LECT2 expression in the tumors, we selected a group of 28
patients for which had serum and corresponding tumor tissue
(Table 2). Intriguingly, no correlation of serum LECT2 to its
mRNA expression was detectable (Figure 3B). Even upon
stratification of tumors for presence (n = 4) or absence (n = 24) of
b-catenin gene mutations, no correlation was evident between
serum LECT2 and its gene expression (Figure 3C–D).
This led us to further investigate if a subset of these tumors with
WT b-catenin gene may still have b-catenin activation. We
examined expression of several surrogate Wnt target genes such as
AXIN2, REGUCALCIN, LECT2 and GLUL in all 28 tumors using
qRT-PCR. Based on the known heterogeneity in Wnt signaling in
HCC, we labeled a tumor to be b-catenin-active if at least 2 of 4
target genes were simultaneously upregulated. In addition to the 4
tumors with CTNNB1 mutations, 12 more samples showed
increased expression of target genes indicative of b-catenin
activation as shown in a heat map (Figure 3E). Based on this
classification, we next compared serum LECT2 levels between
patients with WT b-catenin gene with active Wnt signaling (+) and
with WT b-catenin gene with absent Wnt signaling (2). While
some HCC patients in the former group showed high serum
LECT2 levels, there was no statistical difference between the two
groups (Figure 3F).
Lastly, we compared b-catenin target gene expression among
the three HCC groups; 1) patients with CTNNB1 mutations (MT),
2) patients with WT b-catenin gene but active Wnt signaling (+),
and 3) those with WT b-catenin gene but lacking Wnt signaling
(2). Patients in MT and (+) groups were insignificantly different
from each other in expression values of AXIN2, REGUCALCIN,
LECT2 and GLUL, although the expression was always highest in
the MT group (Figure 3G). However, both these groups showed
significantly higher expression of these four target genes when
compared to the (2) group clearly demonstrating lack of active
Wnt signaling in this subgroup of HCCs (Figure 3D). Intriguingly,
(2) group also showed significantly lower LECT2 expression than
MT and (+) (Figure 3G).
Taken together, these data indicate that despite some HCC
patients showing low LECT2 expression in tumors, they unex-
pectedly still showed high serum LECT2 level with the values
ranging from 50–80 ng/mL.
Increased serum LECT2 is a biomarker of HCC-
independent of b-catenin mutation/activation in tumors
Next, due to heterogeneity in HCC, we investigated if serum
LECT2 levels may be a biomarker of HCC irrespective of a
correlation observed between LECT2 expression in non-b-catenin mutated tumors and serum levels of LECT2 in these HCC patients (n = 24). E. Heat
map shows expression of b-catenin target genes in b-catenin-mutated (MT) and non-mutated wild-type (WT) HCC patients (n = 28). Genes assessed
included AXIN2, REGUCALCIN, LECT2, and GLUL. (+) indicates b-catenin activity as seen by increased expression of at least 2 target genes whereas (2)
indicates absent b-catenin activation reflected by lack of target gene expression. F. Serum LECT2 levels showed insignificant difference in HCC
patients that lacked b-catenin gene mutations but showed high expression of b-catenin target genes versus patients who have neither b-catenin
gene mutations nor any increase in b-catenin target gene expression. G. b-Catenin target gene expression shown by qRT-PCR. Steel-Dwass test was
performed to compare the values among three groups. *, p,0.05. (+) indicates b-catenin activity as seen by increased expression of at least 2 target
genes whereas (2) indicates lack of b-catenin activity due lack of target gene expression.
doi:10.1371/journal.pone.0098817.g003
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precise molecular basis. Intriguingly, Tukey-Kramer analysis
revealed a significant difference in serum LECT2 levels in HCC
patients when compared to chronic liver disease patients with
cirrhosis (p = 0.0017) and healthy volunteers (p = 0.0078)
(Figure 4A). Area Under the Curve (AUC) of 0.82 also highlights
its value as a general biomarker of HCC (Figure 4B). A sub
analysis was done next with LECT2 serum value cut-off at 50 ng/
ml. Fisher Exact test showed significant utility of using .50 ng/ml
of serum LECT2 as an indicator of HCC (two tailed p value,
0.0001) (Figure 4C). Serum LECT2 levels of greater than 50 ng/
ml were able to detect HCC with a sensitivity of 59.3%, specificity
of 96.1%, positive predictive value of 97.0% and negative
predictive value of 53.2%.
Discussion
LECT2 is a secreted protein from hepatocytes functioning like a
chemokine, and is known to be directly regulated by b-catenin
[11,12]. We validated the regulation of this important immune
regulator by the Wnt signaling in HCC. Using hepatocyte-specific
b-catenin KO livers as well as Hep3B cells expressing stable form
of b-catenin, we show that LECT2 expression was indeed b-
catenin-dependent. The major goal of the study was to investigate
if serum LECT2 levels could reflect b-catenin activity in HCC and
hence could be a biomarker to detect HCC-driven by Wnt
signaling for prognostic and therapeutic implications. b-Catenin
therapeutic targeting is indeed actively discussed in HCC [21,22].
At the same time b-catenin inhibition in all HCCs may be
counterproductive due to a paradoxical observation of enhanced
liver injury, inflammation, fibrosis and HCC made in KO exposed
to chemical carcinogen, thus making careful selection of patients of
high relevance [23,24]. Since liver-biopsies may not be feasible in
many HCC patients due to cirrhosis that usually co-exists,
immunohiostochemistry for assessment of b-catenin and/or GS
localization as an indicator of CTNNB1 mutations is often not
possible. Thus there is a significant need for biomarker discovery
for personalized medicine to identify a subset of HCC patients
with b-catenin activation. We hypothesized that serum LECT2
may be a non-invasive way to identify b-catenin gene mutation-
harboring HCC. Indeed previous investigations have shown
LECT2 to be observed systemically, suggesting that it can be a
serum predictor [25,26].
Using mouse model, we confirmed that serum LECT2 levels
indeed correlated with upregulation of Lect2 expression in the
tumor that occurred secondary to b-catenin gene mutations in a
murine HCC model [14]. Based on these observations, we propose
that serum Lect2 levels in mice may be an excellent non-invasive
and simple modality to monitor tumor burden due to b-catenin
gene mutations. Since anti-b-catenin drug discovery is a timely
concept, and models like DEN/PB may be of essence in testing
anti-b-catenin therapies, our studies demonstrate the suitability of
assessing serum Lect2 levels in such models to monitor tumor
response to experimental therapies.
In patient analysis however, serum LECT2 levels were not
statistically different in CTNNB1-mutated versus non-mutated
group. In fact, we did not find any correlation between expression
of Lect2 in the tumors and its corresponding serum levels in a
patient. Since, b-catenin activation in HCC can be due to multiple
independent mechanisms such as overexpression of Wnt inhibi-
tors, increased expression of Wnt3 and Frizzled-7, TGF-b
activation or other reasons [2,7,8,17,22,27,28], we also examined
if serum LECT2 may in fact reflect b-catenin activity rather than
its mutational status. Based on gene expression analysis, we also
identified patients that showed upregulation of b-catenin target
Figure 4. The role of serum LECT2 level as a diagnostic biomarker in HCC. A. Serum LECT2 levels in all HCC patients as compared to patients
with chronic liver fibrosis (CH/LC), and healthy volunteer (HV) as assessed by ELISA. (*p,0.01). B. ROC analysis for the utility of LECT2 as a diagnostic
marker of HCC with AUC= 0.82. C. Fisher’s Exact test shows that based on the cut-off value of serum LECT2 level at 50 ng/mL, sensitivity, specificity,
positive predictive value, negative predictive value for the diagnosis of HCC were 59.3%, 96.1%, 97.0%, and 53.2%, respectively.
doi:10.1371/journal.pone.0098817.g004
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genes but did not harbor any CTNNB1 mutations in exon-3.
While, we did observe b-catenin activation in around 50% more
HCC samples, LECT2 serum levels remained ambiguous in this
subset as well.
Based on the observation of relatively high levels of LECT2 in
serum of a major subset of HCC patients, irrespective of molecular
aberration, we were able to address its utility as a general
biomarker for HCC. A recent study also identified an increase in
serum LECT2 levels in obese individuals and patients with fatty
liver [29]. Since we had only two cirrhosis patients with NASH
and without HCC in our control group, we are unable to study
such correlation in our dataset. Also, we did not attempt to address
any biological implications of Lect2 in HCC in the current study.
However, Lect2 was recently shown to regulate Th2-based
inflammation in HCC [12]. In our analysis, we were unable to
detect any correlation between serum LECT2 levels and
differentiation status of the tumor.
Thus, in summary we have identified Lect2 upregulation in
HCC, both downstream of CTNNB1 mutations and due to
mutation-independent b-catenin activation. While LECT2 serum
levels coincide with Ctnnb1 mutations in mice, this relationship was
ambiguous in patients and Lect2 expression and serum levels did
not correlate with b-catenin activation due to either mutations or
otherwise. However, serum LECT2 by itself turned out to be an
important biomarker of HCC (AUC =0.82). Further, serum
LECT2 levels of greater than 50 ng/ml successfully diagnosed
HCC in patients irrespective with specificity of 96.1% and positive
predictive value of 97.0% and thus should be investigated
prospectively for its diagnostic value.
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